AEON SEC filings, in plain English
Everything Priveterra Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Q2 2026 10-Q of AEON Biopharma, Inc. (NYSE American: AEON), with 49,882,790 shares of Class A common stock outstanding as of August 6, 2026. Why it matters: This summary is drawn from the cover page and cautionary note of the report; the financial statements are not covered here. The quarter's figures and the July 2026 financing are stated in the company's earnings release filed the same day (accession 0001837607-26-000061).
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Exhibit 99.1 to an 8-K of AEON Biopharma, Inc. (NYSE American: AEON): the August 12, 2026 press release reporting Q2 2026 results. Cash and equivalents were $3.4 million at June 30, 2026, which excludes approximately $13.6 million of net upfront proceeds from an underwritten public offering completed in July 2026; the company describes that offering as a $15.3 million financing with milestone warrants that could produce up to an additional $34.0 million of gross proceeds on full cash exercise, and states the upfront proceeds are expected to fund operations into the first quarter of 2027. Why it matters: Cash on the balance sheet at quarter end was $3.4 million; the runway into Q1 2027 depends on the July financing, and the $34.0 million of milestone warrant proceeds is contingent on both milestones and holder exercise. No clinical study for ABP-450 has been agreed with the FDA yet.
What changed: AEON Biopharma, Inc., the Priveterra Acquisition Corp. successor, said that on August 3, 2026 it received a letter from NYSE Regulation confirming it has regained compliance with the NYSE American continued listing standards in Part 10 of the Company Guide, having resolved the previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii). The company expects the below compliance indicator to be removed from its Class A trading symbol and to come off NYSE American's published list of noncompliant issuers. It remains subject to the continued listing standards. Why it matters: Sections 1003(a)(i) and (ii) are the stockholders' equity tests, so regaining compliance means the equity deficiency that put the company on the noncompliant list has been cured rather than merely deferred. Removal of the .BC suffix restores normal quoting and takes away the visible distress marker that keeps some brokers and index products away. For former Priveterra holders it removes near-term delisting risk, though the filing is explicit that a further breach would restart the process.
What changed: AEON Biopharma, Inc., the Priveterra Acquisition Corp. successor, reported that on July 23, 2026 it issued and sold 4,696,102 Class A shares to the underwriters on the representative's partial exercise of the over-allotment option under the July 15, 2026 public offering, for gross proceeds of about $1.5 million and net proceeds of about $1.4 million after discounts and commissions. Lake Street Capital Markets was representative and had already exercised in full the option portion covering the two-year and five-year milestone warrants, each over 6,403,290 shares. Why it matters: The arithmetic reveals the price: about $1.5 million of gross proceeds for 4,696,102 shares implies roughly 32 cents a share. The raise is therefore small in dollars and very large in shares, and the two milestone warrant tranches the representative exercised in full - 6,403,290 shares each, about 12.8 million together - stack substantial further potential issuance on top. That is the defining pattern for a company financing itself off a depressed share price, and existing holders absorb the dilution.
What changed: AEON Biopharma, the Priveterra Acquisition successor, signed an underwriting agreement on July 13, 2026 with Lake Street Capital Markets for a public offering of 17,851,599 Class A shares and pre-funded warrants over 24,837,008 shares, each with one two-year and one five-year milestone warrant. The combined offering price was $0.3221 per share with warrants and $0.3220 per pre-funded warrant with warrants. Why it matters: A combined offering price of about 32 cents is the operative number, and the structure compounds it: roughly 42.7 million shares and pre-funded warrants in the base deal, each carrying a two-year and a five-year milestone warrant, struck at $0.3221 and $0.3704, plus the over-allotment. Pre-funded warrants exercise at $0.0001 so they are economically shares already. The milestone warrants add contingent issuance stretching five years out, on a share count already many times the offering itself.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern and to meet its obligations as they become due within one year after the date”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: AEON Biopharma, Inc., the successor to Priveterra Acquisition Corp., called its 2026 annual meeting for Wednesday, June 17, 2026 at 10:00 a.m. Pacific Time in person at its Irvine, California offices, record date April 21, 2026, at which 26,307,211 shares of Class A Common Stock were outstanding, with 33.34% of voting power required for quorum. Robert Bancroft signs as President and Chief Executive Officer. Why it matters: Routine annual governance for a clinical-stage company whose Priveterra trust was released at the de-SPAC, so the 26.3 million Class A shares carry no floor. The item worth tracking is leadership continuity: a chief executive resigned in spring 2025 with related chairman-level disclosure days later, and the successor faces holders for the first time here. A 33.34% quorum bar means outcomes turn on a modest share of the register.
What changed vs 2025-12-29going concern RESOLVEDgoing-concern doubt1 moved
- Going-concern doubt
- statednot stated
SpacBrain reads this as the substantial-doubt sentence is in the previous filing and not in this one.
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubt, mandate languagenothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Mandate language
- we intend to pursue that offer similar market opportunities.…not matched in this filing
The clause …“that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern. We will require additional financing to fund our future operations. Any failure to obtain”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.